Logo image of ZNTL

ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Fundamental Analysis

NASDAQ:ZNTL - Nasdaq - US98943L1070 - Common Stock - Currency: USD

1.25  0 (0%)

After market: 1.23 -0.02 (-1.6%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ZNTL. ZNTL was compared to 560 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ZNTL as it has an excellent financial health rating, but there are worries on the profitability. ZNTL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ZNTL had negative earnings in the past year.
ZNTL had a negative operating cash flow in the past year.
ZNTL had negative earnings in each of the past 5 years.
ZNTL had a negative operating cash flow in each of the past 5 years.
ZNTL Yearly Net Income VS EBIT VS OCF VS FCFZNTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

ZNTL has a Return On Assets of -58.38%. This is comparable to the rest of the industry: ZNTL outperforms 42.50% of its industry peers.
ZNTL has a Return On Equity (-75.90%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -58.38%
ROE -75.9%
ROIC N/A
ROA(3y)-45.14%
ROA(5y)-40.51%
ROE(3y)-56.86%
ROE(5y)-50.48%
ROIC(3y)N/A
ROIC(5y)N/A
ZNTL Yearly ROA, ROE, ROICZNTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

ZNTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZNTL Yearly Profit, Operating, Gross MarginsZNTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

7

2. Health

2.1 Basic Checks

ZNTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZNTL has been increased compared to 1 year ago.
The number of shares outstanding for ZNTL has been increased compared to 5 years ago.
There is no outstanding debt for ZNTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZNTL Yearly Shares OutstandingZNTL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ZNTL Yearly Total Debt VS Total AssetsZNTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -4.14, we must say that ZNTL is in the distress zone and has some risk of bankruptcy.
ZNTL's Altman-Z score of -4.14 is in line compared to the rest of the industry. ZNTL outperforms 44.82% of its industry peers.
There is no outstanding debt for ZNTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.14
ROIC/WACCN/A
WACC9.53%
ZNTL Yearly LT Debt VS Equity VS FCFZNTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 6.94 indicates that ZNTL has no problem at all paying its short term obligations.
The Current ratio of ZNTL (6.94) is better than 67.50% of its industry peers.
ZNTL has a Quick Ratio of 6.94. This indicates that ZNTL is financially healthy and has no problem in meeting its short term obligations.
ZNTL's Quick ratio of 6.94 is fine compared to the rest of the industry. ZNTL outperforms 67.68% of its industry peers.
Industry RankSector Rank
Current Ratio 6.94
Quick Ratio 6.94
ZNTL Yearly Current Assets VS Current LiabilitesZNTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.12% over the past year.
Looking at the last year, ZNTL shows a very negative growth in Revenue. The Revenue has decreased by -33.76% in the last year.
EPS 1Y (TTM)13.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)-33.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, ZNTL will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.84% on average per year.
ZNTL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.28% yearly.
EPS Next Y-3.79%
EPS Next 2Y2.26%
EPS Next 3Y4.62%
EPS Next 5Y11.84%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-33.97%
Revenue Next 5Y34.28%

3.3 Evolution

ZNTL Yearly Revenue VS EstimatesZNTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2024 2027 2028 2029 2030 2031 2032 200M 400M 600M
ZNTL Yearly EPS VS EstimatesZNTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZNTL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZNTL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZNTL Price Earnings VS Forward Price EarningsZNTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZNTL Per share dataZNTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.26%
EPS Next 3Y4.62%

More info and screens

0

5. Dividend

5.1 Amount

ZNTL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZENTALIS PHARMACEUTICALS INC

NASDAQ:ZNTL (5/29/2025, 8:23:21 PM)

After market: 1.23 -0.02 (-1.6%)

1.25

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners93.32%
Inst Owner Change-8.38%
Ins Owners15%
Ins Owner Change23.46%
Market Cap89.94M
Analysts76.25
Price Target6.09 (387.2%)
Short Float %9.79%
Short Ratio6.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.9%
Min EPS beat(2)13.88%
Max EPS beat(2)13.92%
EPS beat(4)3
Avg EPS beat(4)5.72%
Min EPS beat(4)-44.57%
Max EPS beat(4)39.67%
EPS beat(8)6
Avg EPS beat(8)10.19%
EPS beat(12)8
Avg EPS beat(12)8.51%
EPS beat(16)10
Avg EPS beat(16)7.38%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.84%
PT rev (3m)-4.84%
EPS NQ rev (1m)5.02%
EPS NQ rev (3m)14.68%
EPS NY rev (1m)0%
EPS NY rev (3m)9.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.35
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.3
EV/EBITDA N/A
EPS(TTM)-2.98
EYN/A
EPS(NY)-2.18
Fwd EYN/A
FCF(TTM)-2.11
FCFYN/A
OCF(TTM)-2.11
OCFYN/A
SpS0.37
BVpS4.11
TBVpS4.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -58.38%
ROE -75.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.14%
ROA(5y)-40.51%
ROE(3y)-56.86%
ROE(5y)-50.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.75%
Cap/Sales 0.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.94
Quick Ratio 6.94
Altman-Z -4.14
F-Score2
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)79.15%
Cap/Depr(5y)368.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next Y-3.79%
EPS Next 2Y2.26%
EPS Next 3Y4.62%
EPS Next 5Y11.84%
Revenue 1Y (TTM)-33.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-33.97%
Revenue Next 5Y34.28%
EBIT growth 1Y23.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-33.06%
EBIT Next 3Y-12.88%
EBIT Next 5YN/A
FCF growth 1Y8.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.94%
OCF growth 3YN/A
OCF growth 5YN/A